135 related articles for article (PubMed ID: 36867101)
1. Design, Synthesis, and Anti-Cancer Evaluation of Novel Cyclic Phosphate Prodrug of Gemcitabine.
Zhang L; Qi K; Xu J; Xing Y; Wang X; Tong L; He Z; Xu W; Li X; Jiang Y
J Med Chem; 2023 Mar; 66(6):4150-4166. PubMed ID: 36867101
[TBL] [Abstract][Full Text] [Related]
2. Enhanced Antitumor Activity of Monophosphate Ester Prodrugs of Gemcitabine: In Vitro and In Vivo Evaluation.
Qi H; Lu J; Li J; Wang M; Xu Y; Wang Y; Zhang H
J Pharm Sci; 2016 Sep; 105(9):2966-2973. PubMed ID: 26994559
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of Gemcitabine-Threonine Amide Prodrug Effective on Pancreatic Cancer Cells with Improved Pharmacokinetic Properties.
Hong S; Fang Z; Jung HY; Yoon JH; Hong SS; Maeng HJ
Molecules; 2018 Oct; 23(10):. PubMed ID: 30314360
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine-based therapy for pancreatic cancer using the squalenoyl nucleoside monophosphate nanoassemblies.
Maksimenko A; Caron J; Mougin J; Desmaële D; Couvreur P
Int J Pharm; 2015 Mar; 482(1-2):38-46. PubMed ID: 25448549
[TBL] [Abstract][Full Text] [Related]
5. Development of Fluorophosphoramidate as a Biocompatibly Transformable Functional Group and its Application as a Phosphate Prodrug for Nucleoside Analogs.
Yoshida Y; Zheng T; Tanabe W; Tomoike F; Hashiya F; Suzuki T; Hirota S; Saiki Y; Horii A; Hirayama A; Soga T; Kimura Y; Abe H
ChemMedChem; 2022 Sep; 17(17):e202200188. PubMed ID: 35393747
[TBL] [Abstract][Full Text] [Related]
6. Application of ProTide technology to gemcitabine: a successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical development.
Slusarczyk M; Lopez MH; Balzarini J; Mason M; Jiang WG; Blagden S; Thompson E; Ghazaly E; McGuigan C
J Med Chem; 2014 Feb; 57(4):1531-42. PubMed ID: 24471998
[TBL] [Abstract][Full Text] [Related]
7. Potential Development of Tumor-Targeted Oral Anti-Cancer Prodrugs: Amino Acid and Dipeptide Monoester Prodrugs of Gemcitabine.
Tsume Y; Drelich AJ; Smith DE; Amidon GL
Molecules; 2017 Aug; 22(8):. PubMed ID: 28796151
[TBL] [Abstract][Full Text] [Related]
8. Theranostic reduction-sensitive gemcitabine prodrug micelles for near-infrared imaging and pancreatic cancer therapy.
Han H; Wang H; Chen Y; Li Z; Wang Y; Jin Q; Ji J
Nanoscale; 2016 Jan; 8(1):283-91. PubMed ID: 26608864
[TBL] [Abstract][Full Text] [Related]
9. Polyisoprenoyl gemcitabine conjugates self assemble as nanoparticles, useful for cancer therapy.
Maksimenko A; Mougin J; Mura S; Sliwinski E; Lepeltier E; Bourgaux C; Lepêtre S; Zouhiri F; Desmaële D; Couvreur P
Cancer Lett; 2013 Jul; 334(2):346-53. PubMed ID: 22935679
[TBL] [Abstract][Full Text] [Related]
10. Hyaluronic acid-coated, prodrug-based nanostructured lipid carriers for enhanced pancreatic cancer therapy.
Lu Z; Su J; Li Z; Zhan Y; Ye D
Drug Dev Ind Pharm; 2017 Jan; 43(1):160-170. PubMed ID: 27553814
[TBL] [Abstract][Full Text] [Related]
11. Novel approaches for designing 5'-O-ester prodrugs of 3'-azido-2', 3'-dideoxythymidine (AZT).
Parang K; Wiebe LI; Knaus EE
Curr Med Chem; 2000 Oct; 7(10):995-1039. PubMed ID: 10911016
[TBL] [Abstract][Full Text] [Related]
12. A Hydrogen Peroxide Activatable Gemcitabine Prodrug for the Selective Treatment of Pancreatic Ductal Adenocarcinoma.
Matsushita K; Okuda T; Mori S; Konno M; Eguchi H; Asai A; Koseki J; Iwagami Y; Yamada D; Akita H; Asaoka T; Noda T; Kawamoto K; Gotoh K; Kobayashi S; Kasahara Y; Morihiro K; Satoh T; Doki Y; Mori M; Ishii H; Obika S
ChemMedChem; 2019 Aug; 14(15):1384-1391. PubMed ID: 31207139
[TBL] [Abstract][Full Text] [Related]
13. Pancreatic adenocarcinoma preferentially takes up and is suppressed by synthetic nanoparticles carrying apolipoprotein A-II and a lipid gemcitabine prodrug in mice.
Smith RC; Bulanadi JC; Gill AJ; Rye KA; Hugh T; Proschogo N; Smith SF; Phillips L; Gong X; Julovi SM; Xue A; Moghaddam MJ
Cancer Lett; 2020 Dec; 495():112-122. PubMed ID: 32949679
[TBL] [Abstract][Full Text] [Related]
14. Novel ProTide prodrugs of 5-fluoro-2'-deoxyuridine for the treatment of liver cancer.
Jiang L; Pan T; Lv Q; Yuan W; Liu X; Qu X; Luo D; Wan S; Cui S
Eur J Med Chem; 2023 Nov; 260():115763. PubMed ID: 37659196
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and anticancer evaluation of acetylated-lysine conjugated gemcitabine prodrugs.
Wang M; Qu K; Zhao P; Yin X; Meng Y; Herdewijn P; Liu C; Zhang L; Xia X
RSC Med Chem; 2023 Aug; 14(8):1572-1580. PubMed ID: 37593582
[TBL] [Abstract][Full Text] [Related]
16. In vitro evaluation of novel N-acetylalaninate prodrugs that selectively induce apoptosis in prostate cancer cells.
McGoldrick CA; Jiang YL; Brannon M; Krishnan K; Stone WL
BMC Cancer; 2014 Sep; 14():675. PubMed ID: 25234292
[TBL] [Abstract][Full Text] [Related]
17. Nucleoside ester prodrug substrate specificity of liver carboxylesterase.
Landowski CP; Lorenzi PL; Song X; Amidon GL
J Pharmacol Exp Ther; 2006 Feb; 316(2):572-80. PubMed ID: 16223870
[TBL] [Abstract][Full Text] [Related]
18. Novel cyclic phosphate prodrug approach for cytochrome P450-activated drugs containing an alcohol functionality.
Huttunen KM; Mähönen N; Leppänen J; Vepsäläinen J; Juvonen RO; Raunio H; Kumpulainen H; Järvinen T; Rautio J
Pharm Res; 2007 Apr; 24(4):679-87. PubMed ID: 17372695
[TBL] [Abstract][Full Text] [Related]
19. Tissue-Specific Proteomics Analysis of Anti-COVID-19 Nucleoside and Nucleotide Prodrug-Activating Enzymes Provides Insights into the Optimization of Prodrug Design and Pharmacotherapy Strategy.
Li J; Liu S; Shi J; Wang X; Xue Y; Zhu HJ
ACS Pharmacol Transl Sci; 2021 Apr; 4(2):870-887. PubMed ID: 33855276
[TBL] [Abstract][Full Text] [Related]
20. Self-Assembled Gemcitabine Prodrug Nanoparticles Show Enhanced Efficacy against Patient-Derived Pancreatic Ductal Adenocarcinoma.
Wu L; Zhang F; Chen X; Wan J; Wang Y; Li T; Wang H
ACS Appl Mater Interfaces; 2020 Jan; 12(3):3327-3340. PubMed ID: 31872760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
